Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 3/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25688843 | 0.97 | P2RY12 (0.38) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL25693011 | 0.96 | P2RY12 (0.34) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL22220012 | 0.95 | P2RY12 (0.33) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL25688857 | 0.92 | P2RY12 (0.38) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL20792369 | 0.91 | P2RY12 (0.35) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL22220013 | 0.91 | P2RY12 (0.35) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL25688848 | 0.90 | P2RY12 (0.40) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL20691314 | 0.88 | P2RY12 (0.36) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL24321986 | 0.87 | P2RY12 (0.37) | P2RY12DNPH1P2RY2P2RY1P2RY6 | |
| SCHEMBL22219998 | 0.87 | P2RY12 (0.35) | P2RY12DNPH1P2RY2P2RY1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | P2RY12 1351/4885DNPH1 1732/4885P2RY2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.